- Home
- MLYS vs FFC Comparison
MLYS vs FFC Comparison
Compare MLYS & FFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- FFC
- Stock Information
- Founded
- MLYS 2019
- FFC 1983
- Country
- MLYS United States
- FFC United States
- Employees
- MLYS N/A
- FFC N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- FFC Trusts Except Educational Religious and Charitable
- Sector
- MLYS Health Care
- FFC Finance
- Exchange
- MLYS Nasdaq
- FFC Nasdaq
- Market Cap
- MLYS 893.0M
- FFC 767.5M
- IPO Year
- MLYS 2023
- FFC N/A
- Fundamental
- Price
- MLYS $13.35
- FFC $15.06
- Analyst Decision
- MLYS Strong Buy
- FFC
- Analyst Count
- MLYS 3
- FFC 0
- Target Price
- MLYS $33.00
- FFC N/A
- AVG Volume (30 Days)
- MLYS 1.3M
- FFC 164.1K
- Earning Date
- MLYS 05-08-2025
- FFC 01-01-0001
- Dividend Yield
- MLYS N/A
- FFC 6.79%
- EPS Growth
- MLYS N/A
- FFC N/A
- EPS
- MLYS N/A
- FFC N/A
- Revenue
- MLYS N/A
- FFC N/A
- Revenue This Year
- MLYS N/A
- FFC N/A
- Revenue Next Year
- MLYS N/A
- FFC N/A
- P/E Ratio
- MLYS N/A
- FFC N/A
- Revenue Growth
- MLYS N/A
- FFC N/A
- 52 Week Low
- MLYS $8.24
- FFC $11.90
- 52 Week High
- MLYS $18.38
- FFC $14.96
- Technical
- Relative Strength Index (RSI)
- MLYS 49.65
- FFC 43.57
- Support Level
- MLYS $10.44
- FFC $14.60
- Resistance Level
- MLYS $14.83
- FFC $15.26
- Average True Range (ATR)
- MLYS 1.49
- FFC 0.36
- MACD
- MLYS -0.14
- FFC -0.02
- Stochastic Oscillator
- MLYS 43.24
- FFC 46.74
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
About FFC Flaherty & Crumrine Preferred and Income Securities Fund Incorporated
Flaherty & Crumrine Preferred and Income Securities Fund Incorporated is a diversified, closed-end management investment company. The fund's investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. It invests in a diversified portfolio of preferred securities.